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Abstract
Background and aims: Extensive evidence has underlined the importance of mucosal healing as a 
treatment aim for ulcerative colitis (UC). We aimed to assess differences in the incidence of clinical 
relapse at 12 months between UC patients with Mayo endoscopic scores (MES) 0 and 1.
Methods: This retrospective study included consecutive patients in corticosteroid-free remission 
between 2008 and 2013 and with follow-up of at least 1  year, with MES 0 or 1 in complete 
colonoscopy. Clinical relapse was defined as need for induction treatment, treatment escalation, 
hospitalization or surgery. A p value <0.05 was considered statistically significant.
Results: The study included 138 patients, 72 (52.2%) female, with mean age of 49 (±14) years. 
Inflammatory activity was classified as MES 0 in 61 (44.2%) patients and MES 1 in 77 (55.8%) 
patients. Clinical relapse during follow-up was significantly more frequent in patients with MES 1 
than MES 0 (27.3 vs 11.5%, p = 0.022), and in the multivariate analysis MES 1 was the only factor 
significantly associated with an increased risk of relapse (odds ratio 2.89, 95% confidence interval 
1.14–7.36, p = 0.026). This association was encountered in the subgroup of patients with left-sided/
extensive colitis (29.7 vs 11.1%, p = 0.049), but not proctitis (25.0 vs 12.0%, p = 0.202).
Conclusions: In patients with UC in corticosteroid-free remission, particularly those with left-sided 
colitis or extensive colitis, MES 1 was significantly associated with a 3-fold increased risk of relapse 
compared with endoscopic MES 0. Our results support the use of endoscopic MES 0 as the most 
suitable treatment endpoint to define mucosal healing in patients with UC.
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1. Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of 
unknown aetiology, with an increasing prevalence, reaching up to 
505 per 100 000,1,2 characterized by periods of remission and periods 
of relapse.3
Traditionally, UC treatment was aimed at the relief of disease-
related signs and symptoms, such as diarrhoea, rectal bleeding, 
abdominal pain, weight loss and malaise.4 However, the correlation 
between symptoms and endoscopic findings is imperfect,5 and almost 
half of all patients in clinical remission present with colonic mucosal 
inflammation.6 Moreover, drugs such as corticosteroids have been 
shown to significantly improve clinical symptoms but provide mod-
est benefits in improving mucosal lesions.7 In recent years, prospec-
tive studies have associated mucosal healing with reduced rates of 
disease relapse, hospital admission and surgery,8–12 as well as a lower 
cumulative risk of dysplasia and colorectal cancer progression.11,13,14 
Current treatment strategies are aimed at achieving mucosal heal-
ing in UC patients,3,13 which is widely considered the gold standard 
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for assessing disease activity. Several indices were developed to more 
accurately define and evaluate mucosal healing in UC,13,15–18 of which 
the most often used in clinical trials is the Mayo endoscopic score 
(MES).8,9 The MES is a component of the Mayo score,19 and classi-
fies mucosal inflammation from 0 to 3 on the basis of the vascular 
pattern, erythema, friability, erosions and ulcers.
Currently, accepted endpoints for mucosal healing in UC include 
MES 0 (normal mucosa) and MES 1 (erythema and decreased vas-
cular pattern may be present),9,12,20 but some authors have suggested 
a more restricted definition of mucosal healing: an MES of 0.8,21,22
The aim of this study was to compare clinical outcomes in UC 
patients in sustained corticosteroid-free remission with MES 0 and 
MES 1.
2. Methods
We performed a retrospective single-centre study including consecu-
tive UC patients in sustained corticosteroid-free remission (≥6 months) 
undergoing endoscopic evaluation between January 2009 and 
December 2013. Patients having a complete colonoscopy with MES 
0 or MES 1 were included. All patients had a previously established 
diagnosis of UC, were followed as outpatients and were receiving UC 
medication. Patients with absence of follow-up, medication adjust-
ment or loss of compliance between endoscopic evaluation and out-
come assessment, colorectal cancer or pregnancy were excluded.
Clinical disease activity was evaluated using the partial Mayo 
score, previously used in several clinical trials,20,23,24 including the 
rectal bleeding and stool frequency subscales only, as this score 
has shown a good correlation with the Mayo score and eliminates 
the potentially confounding physician’s global assessment variable 
(subjective assessment, prone to interobserver variability).23 Clinical 
remission was defined as a rectal bleeding subscore of 0 (no rectal 
bleeding) and a stool frequency subscore of either 0 (normal stool 
frequency for the patient) or 1 (1 or 2 more daily stools than normal).
Bowel preparation was achieved with a polyethylene glycol-
based electrolyte solution, and patients with incomplete colonoscopy 
or inadequate bowel preparation were excluded.
Endoscopic evaluation was performed by a single gastroenter-
ologist with significant inflammatory bowel disease experience 
(>15 years of practice), using the Montreal classification25 for disease 
extent (E1, proctitis, disease limited to the rectum; E2, left-sided coli-
tis, disease involvement proximal to the rectosigmoid junction and 
distal to the splenic flexure; E3, extensive colitis, disease involvement 
proximal to the splenic flexure) and a modified MES20 for disease 
inflammatory activity, where the presence of any friability is consid-
ered MES 2. Patients were considered to have MES 0 if there was 
normal mucosa in all colonic segments and MES 1 if erythema or a 
decreased vascular pattern was observed.
Laboratory data were obtained at the time of the colonoscopy, 
including complete blood count, C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR), iron, total iron-binding capacity, fer-
ritin, total proteins and albumin.
Clinical data were analysed for a defined period of 12 months 
of follow-up after total colonoscopy, and clinical relapse during this 
period was considered as the need for intensification or modification 
of medication, UC-related hospital admission or surgery. A second-
ary analysis was performed for the incidence of adverse events during 
follow-up, defined as the need for corticosteroid therapy or immuno-
suppressants, as well as UC-related hospitalization or surgery.
Statistical analysis was performed using SPSS 21.1™ (WinWrap 
Basics™). Univariate analyses were performed using the independent 
samples t test for continuous variables and the χ2 test for categorical 
variables, and multivariate analysis was performed using a logistic 
regression model with calculation of odds ratios and 95% confidence 
intervals. A Kaplan–Meier curve for duration of clinical remission 
during follow-up was generated for patients with MES 0 and MES 
1, and compared with a 2-side log-rank test. A Cox hazard regres-
sion model was used to calculate hazard ratios for disease relapse. 
Statistical significance was defined as p < 0.05 and quantitative vari-
ables were presented as mean ± SD.
3. Results
One hundred and thirty-eight patients were included during the 
5-year period, with a mean age of 49 ± 14 years); 52% (n = 72) were 
female. Most patients (67.4%, n  =  93) were non-smokers, and 8 
(5.8%) had a family history of inflammatory bowel disease. The 
majority of the patients (78.3%; n = 108) were being treated with 
aminosalicylates alone, while 21.7% (n  =  30) were under immu-
nosuppressant/immunomodulator therapy; of these, 7.2% (n = 10) 
were treated with azathioprine in monotherapy, 12.3% (n  =  17) 
with azathioprine and aminosalicylates, and 2.2% (n  = 3)  with 
azathioprine and the anti-tumour necrosis factor α (TNFα) agent 
infliximab.
Mean haemoglobin (14.1  ±  1.6  g/dL), leucocyte 
(7.0 ± 2.1 × 103/μL), platelet (239 ± 59 × 103/μL), CRP (3.1 ± 3.1 mg/L), 
ESR (14.1 ± 11.3 mm/h) and albumin (4.4 ± 0.5 mg/dL) serum levels 
were within the normal range.
Disease distribution was limited to the rectum in 46.4% (n = 64) 
of the patients, while 27.5% (n  =  38) had left-sided colitis and 
26.1% (n = 26) had extensive colitis; in the assessment of disease 
activity, MES 0 was observed in 44.2% (n = 61) patients and MES 1 
in 55.8% (n = 77). Table 1 summarizes the patients’ clinical, labora-
tory and endoscopic characteristics.
The two groups of patients with MES 0 and MES 1 were homo-
geneous, with no statistically significant differences between them in 
either clinical or laboratory variables (Table 2).
During the 12-month follow-up period, clinical relapse was 
observed in 20.3% (n = 28) of the patients, with a mean interval 
between colonoscopy and relapse of 5.6 (SD ± 2.9) months. In these 
28 patients, intensification of the current therapy was needed in 16 
(57.1%), corticosteroids were started in 6 (21.4%), a decision to 
start azathioprine was made in 5 (17.9%), and in 2 (7.1%) patients 
an anti-TNFα agent was added to azathioprine; finally, 3 (10.7%) of 
the patients with clinical relapse had a hospital admission and were 
started on systemic corticosteroids, and in one of them an anti-TNFα 
drug was started.
In the univariate analysis, younger age at colonoscopy 
(44.2 ± 12.7 vs 50.1 ± 14.0 years, p = 0.045) and MES 1 (27.3 vs 
11.5%, p = 0.022) were associated with an increased risk of clini-
cal relapse, but MES 1 was the only variable associated with an 
increased risk of clinical relapse in the multivariate analysis (MES 1: 
odds ratio 2.89, 95% confidence interval 1.137–7.358, p = 0.026). 
The Kaplan–Meier curves of recurrence-free survival for patients 
with MES 1 and MES 0 are shown in Figure 1.
The incidence of relapse during follow-up in patients with MES 
1 when compared with MES 0 was also significantly superior in the 
subgroup of patients with left-sided/extensive colitis (29.7 vs 11.1%, 
p = 0.049), but not in patients with disease limited to the rectum 
(25.0 vs 12.0%, p = 0.202). The interval between colonoscopy and 
clinical relapse was not significantly different between patients with 
MES 1 and MES 0 (4.0 ± 2.0 vs 6.1 ± 3.1, p = 0.105).
Overall, MES 1 was significantly associated with an increased 
risk of adverse outcomes (13.0 vs 3.3%, p = 0.044), although we 
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encountered no differences between patients with MES 1 and MES 
0 regarding each individual outcome: need for corticosteroid ther-
apy (5.2 vs 3.3%, p = 0.584), immunosuppressants (9.1 vs 3.3%, 
p = 0.170) or hospitalization (2.6 vs 1.6%, p = 0.702). No patient 
was submitted to surgery during follow-up.
4. Discussion
In this study we demonstrated that in UC patients in sustained 
corticosteroid-free remission with MES ≤1, more than one-fifth 
will present with clinical relapse during 12  months of follow-up. 
Additionally, we encountered a 3-fold risk of clinical relapse in 
patients presenting with MES 1 compared with MES 0.
Both UC and CD are inflammatory bowel diseases, characterized 
by periods of remission and periods of relapse, carrying a signifi-
cant morbidity burden,11 directing previous treatment goals towards 
achieving symptom remission.26 However, correlation between symp-
toms and inflammatory activity in UC is poor, and clinical assess-
ment is often insufficient for a precise treatment approach.22,27,28
The concept of mucosal healing has been discussed for over 
60 years,15 and has recently become a preferred treatment endpoint 
for UC patients.3,13
The importance of mucosal healing was shown in two landmark 
studies using the MES. In the IBSEN Group study, performed in the 
pre-anti-TNFα era, mucosal healing was significantly associated with 
a reduced risk of colectomy,10 and in the combined analysis of ACT 
1 and ACT 2 trials, patients with MES ≤1 at week 8 of infliximab 
treatment were significantly less likely to present with clinical relapse 
or need for corticosteroids at weeks 30 and 54, and progressed less 
frequently to colectomy.8 Other authors have shown mucosal healing 
to be associated with lower risks of clinical relapse,7,9,24 hospitaliza-
tion,7,13 immunosuppressant use7 and colectomy,7,29,30 and long-term 
follow-up of UC patients demonstrated a lower risk of dysplasia and 
colorectal cancer,31 often undistinguishable from the normal popu-
lation risk, in the presence of colonic mucosal healing.14 Finally, a 
negative correlation between endoscopic inflammatory activity and 
patients’ quality of life has been reported.32
Nevertheless, the definition of mucosal healing in UC patients 
is still a contentious topic; it was considered in 2007 by the 
International Organization for the Study of Inflammatory Bowel 
Disease as the absence of friability, blood, erosions and ulcers in all 
segments of gut mucosa.28 The endoscopic component of the Mayo 
score, created in 1987,19 included the variables erythema, decreased 
vascular pattern, friability, erosions and ulcers, and has become 
the most often employed score in clinical trials,13 particularly the 
modified MES, where mild friability is considered MES 2 and not 
MES 1.8,9 Current ECCO guidelines define endoscopic remission as 
MES ≤1 and complete endoscopic remission is considered for MES 
0 only.13
In our study, MES 1 was significantly associated with an 
increased risk of clinical relapse compared with MES 0 (27.3 vs 
11.5%, p = 0.022), as well as an increased risk of hospitalization 
or the need for corticosteroid or immunosuppressant drugs (13.0 vs 
3.3%, p = 0.044). Very few studies have reported differences in clini-
cal outcomes between patients with MES 0 and MES 1. Our results 
are in line with those obtained by Colombel et al.,8 where patients 
with MES 0 at week 8 of infliximab were significantly more often in 
corticosteroid-free remission after 1 year of follow-up than patients 
Table 1. Patient characteristics (global).
Female (%) 52.2
Age at colonoscopy, y
(mean ± SD)
48.9 ± 13.9
Age at diagnosis, y
(mean ± SD)
40.9 ± 13.8
Disease duration, y
(mean ± SD)
8.0 ± 6.7
Smoking status (%)
 Former smoker 27.9
 Smoker 9.8
 Non-smoker 62.3
Family history of inflammatory bowel disease (%) 5.8
Medication (%)
 5-ASA 78.7
 5-ASA + immunosuppressants 9.8
 Immunosuppressants 11.5
Haemoglobin, g/dL (mean ± SD) 14.1 ± 1.6
Leucocytes, 103/μL (mean ± SD) 7.0 ± 2.1
Platelets, 103/μL (mean ± SD) 239 ± 59
ESR, mm/h (mean ± SD) 14.1 ± 11.3
CRP, mg/L (mean ± SD) 4.1 ± 3.8
Ferritin, ng/mL (mean ± SD) 138 ± 113
Albumin, mg/dL (mean ± SD) 4.5 ± 0.5
Disease distribution (%)
 Proctitis (E1) 46.4
 Left-sided colitis (E2) 27.5
 Extensive colitis (E3) 26.1
Disease activity (%)
 MES 0 44.2
 MES 1 55.8
5-ASA, 5-aminosalicylates; CRP, C-reactive protein; ESR, erythrocyte sedi-
mentation rate; MES, Mayo endoscopic score.
Table 2. Patient characteristics.
MES 0 MES 1 p
Female (%) 50.8 53.2 0.777
Age at colonoscopy, y
(mean ± SD)
49.8 ± 14.3 48.1 ± 13.7 0.477
Age at diagnosis, y
(mean ± SD)
42.5 ± 14.2 39.7 ± 13.5 0.239
Disease duration, y
(mean ± SD)
7.4 ± 6.0 8.5 ± 7.2 0.345
Smoking status (%)
 Former smoker 27.9 18.6 0.206
 Smoker 9.8 12.0
 Non-smoker 62.3 69.4
Family history of inflammatory 
bowel disease (%)
4.9 6.5 1.000
Medication (%)
 5-ASA 78.7 77.9 0.914
 5-ASA + immunosuppressants 9.8 9.1
 Immunosuppressants 11.5 13.0
Haemoglobin, g/dL (mean ± SD) 14.2 ± 1.5 14.1 ± 1.7 0.728
Leucocytes, 103/μL (mean ± SD) 7.0 ± 2.8 7.0 ± 2.3 0.901
Platelets, 103/μL (mean ± SD) 247 ± 56 234 ± 61 0.195
ESR, mm/h (mean ± SD) 16.4 ± 13.7 13.9 ± 13.6 0.093
CRP, mg/L (mean ± SD) 4.1 ± 3.8 4.2 ± 4.4 0.642
Ferritin, ng/mL (mean ± SD) 138 ± 113 123 ± 100 0.435
Albumin, mg/dL (mean ± SD) 4.5 ± 0.5 4.4 ± 0.6 0.491
Disease distribution (%)
 Proctitis (E1) 41.0 51.3 0.369
 Left-sided colitis (E2) 32.8 23.7
 Extensive colitis (E3) 26.2 25.0
5-ASA, 5-aminosalicylates; CRP, C-reactive protein; ESR, erythrocyte sedi-
mentation rate; MES, Mayo endoscopic score.
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with MES 1 (73 vs 47%, p < 0.001); Nakarai et al.,24 who reported 
significantly increased risks of clinical relapse, need for corticos-
teroids and hospitalization in MES 1 patients in clinical remission 
when compared with MES 0; and Yokoyama et al.,33 who demon-
strated significant differences in long-term maintenance of remission 
between patients with MES 0 and MES 1 (93 vs 70%, p < 0.001). In 
contrast, Meucci et al.9 reported no differences in the maintenance of 
remission with mesalamine in patients with MES 0 and MES 1, while 
MES 2 was associated with an increased risk of relapse.
We report as well a significantly higher risk of relapse in patients 
with MES 1 in the subgroup of patients with left-sided or extensive 
colitis (29.7 vs 11.1%, p = 0.049), but no significant differences were 
observed in those patients presenting with proctitis (25.0 vs 12.0%, 
p  = 0.202). This new evidence may be explained by a heightened 
importance of complete mucosal healing in a colon with extensive 
inflammatory tissue damage and increased complexity in adequately 
differentiating MES 0 and MES 1 in the rectal mucosa, but because 
clinical relapse was twice as frequent with MES 1 than it was with 
MES 0 in patients with proctitis, a type II error may not be safely 
excluded. Further studies with larger sample sizes may be warranted 
to clarify this topic. New technologies, such as narrow-band imag-
ing and magnifying endoscopy, may also allow greater detail during 
mucosal observation and assist in identifying patients with a supe-
rior risk of relapse.34
Histological healing as a target in UC is increasingly a topic of 
discussion, and markers of histological inflammation, such as basal 
plasmacytosis35 and an elevated Geboes score,36 have been associated 
with a higher incidence of clinical relapse. In our study no histo-
logical analysis was performed, but Guardiola et al.37 demonstrated 
that only 7% of patients with MES 0 had significant histological 
inflammatory activity compared with 52% of those with MES 1 
(p < 0.001), and Lemmens et al.38 reported that MES 0 accurately 
reflected normal histology in biopsies. Nevertheless, using histologi-
cal healing as an endpoint in UC is still hindered by the following: 
a validated and easily reproducible histological index is needed for 
clinical practice; few studies have evaluated the impact of current 
drugs, particularly anti-TNFα agents, in achieving histological heal-
ing; and data regarding long-term outcomes, such as disease progres-
sion, hospitalization and surgery, are still insufficient.22,28,39
The prognostic use of serum or faecal markers in patients with 
UC has been studied extensively as a potential technique to reduce 
the need for costly and invasive endoscopic procedures, but recent 
studies have shown inconsistent results, both for CRP6,35,40,41 and for 
ESR.40,41 In our work, neither inflammatory marker was associated 
with an increased risk of adverse outcomes and neither correlated 
with endoscopic inflammatory activity, but, unlike other studies, our 
analysis was restricted to patients in corticosteroid-free remission 
with MES ≤1. The modest correlations between serum markers and 
UC endoscopic activity when compared with CD patients may be 
explained by the fact that CD is a transmural disease, leading to 
higher serum concentrations of the pro-inflammatory interleukin 
IL-6.42
Finally, calprotectin is a faecal biomarker showing a good corre-
lation with endoscopic inflammation in both CD and UC and dem-
onstrated promising results in predicting clinical relapse,43,44 but its 
use in clinical practice is limited by both inter- and intra-assay vari-
ability and lack of defined cutoff levels.45,46
Our work has some limitations: it was a unicentric retrospective 
study using the Mayo endoscopic score and had a short follow-up 
period. Nonetheless, the short period of follow-up and the fact that 
it was an observational study based on prospectively collected data 
reduced the risk of intervention bias. The limitations of the Mayo 
score, a non-validated score with significant inter-observer variabil-
ity,22 were partially attenuated by excluding the physician’s global 
assessment, a subjective variable that is prone to bias, particularly 
in retrospective studies,8,20 and by considering mucosal friability 
in the exclusion criteria (MES 2) and restricting the realization of 
colonoscopies by a single gastroenterologist. Moreover, because 
mucosal healing often lags behind the achievement of clinical remis-
sion,11 the strict inclusion criteria of patients with at least 6 months 
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Figure 1. Kaplan–Meier curves of recurrence-free survival for patients with Mayo endoscopic score 0 and 1, using the log-rank test.
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of corticosteroid-free remission allows for exclusion of patients who 
might have MES 1 at the time of endoscopic evaluation but who are 
still progressing to complete mucosal healing.
In conclusion, in our study, patients with MES 1 were at a sta-
tistically significant 3-fold increased risk of clinical relapse during 
follow-up and significantly more likely to need corticosteroids, pro-
gress to immunosuppression therapy or warrant hospitalization. 
In particular, patients with left-sided or extensive colitis benefited 
the most from complete mucosal healing. These results support the 
importance of endoscopic assessment of patients in clinical remis-
sion and the use of endoscopic Mayo score 0 as the most suitable 
treatment endpoint to achieve mucosal healing in UC patients.
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